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Phangisile Manciya MtshaliWhen the World Health Organization (WHO) intro-
duced its first-ever global health sector strategy on viral
hepatitis in May 2016, it charged the global community
with the goal of eliminating viral hepatitis as a public
health threat by 2030. The strategy defines this achieve-
ment quantitatively in terms of a number of key targets
including a 90% reduction in new chronic hepatitis B
virus (HBV) and hepatitis C virus (HCV) infections and
a 65% reduction in HBV and HCV deaths by 2030 [1].
The sought-after reductions in incidence and mortality
are huge – and at the same time, the strong arsenal of
tools at our disposal provides reason for optimism about
what can be achieved.
Given the immense burden of HBV and HCV in China
and India, however, it simply will not be possible to
achieve the WHO targets without taking new measures
to meet the challenges facing these two countries. An es-
timated 5.5% of China’s population of 1.4 billion has the
hepatitis B surface antigen (HBsAg). Between 0.2 and
1.2% of the adult population is thought to be HCV
RNA-positive [2]. India has a population of 1.2 billion
and an estimated HBsAg prevalence level of 1.5% [2],
while its estimated adult HCV RNA prevalence level is
between 0.4 and 0.8% [3].
The sizes of these countries mean that their disease
burdens contribute enormously to global disease bur-
dens. China and India together account for a staggering
37% of all estimated cases of HbsAg infection and 20%
of all estimated adult cases of HCV RNA infection
worldwide [2, 3].
In this context, the logical question might seem to be:
what does the global community need to do to aid India
and China? However, the editors of this thematic series
on HBV and HCV in India and China would like to re-
frame the question and urge people working in diverse
settings worldwide to consider: what can the world learn
from India and China, in terms of how the community-
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are responding to complex viral hepatitis-related
challenges?
These are, after all, both middle-income countries that
have developed policy frameworks for addressing health
needs. China has attracted global attention for its activ-
ities in the burgeoning field of precision medicine, with
large-scale initiatives exploring genetic links to major
diseases [4]. In India, a combination of pharmaceutical
manufacturing capacity and political will helped with the
expansion of the global HIV drug market, supported by
technology transfer from and partnership with research
and development-based pharmaceutical companies. The
more affordable generic alternatives from India have
contributed enormously to progress against HIV in low-
income countries [5]. Both countries continue to priori-
tise many important forms of health research through
public-sector and private-sector channels and to demon-
strate the value of this work to the global community.
Hence my colleagues and I are intrigued by the ques-
tion of how grassroots and community-based develop-
ments in India and China will contribute to progress in
the movement to eliminate viral hepatitis, and particu-
larly to ending illness and death from chronic HBV and
HCV. The articles in this thematic series provide a fas-
cinating window into the diversity of research activities
taking place on the ground in Chinese and Indian com-
munities. In the first article that was published in the
series, Chari Cohen and colleagues reported on hepatitis
B-related knowledge, attitudes and practices following a
citywide public health education program in Haimen
City, China, documenting the persistence of stigma in
spite of high knowledge levels [6]. This was followed by
Hai-Yang Zhou and colleagues’ article on health insur-
ance coverage and medical costs associated with chronic
HCV infection in 20 provinces in China [7].
The next article in the series, by Swati Jha and col-
leagues, reported on findings from a cross-sectional
survey assessing HBV knowledge among women of
childbearing age in poor communities in Mumbai, India
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data from large cohorts of people who inject drugs in
two Indian cities to explore how predisposing, enabling,
and need factors might contribute to different levels of
HCV testing uptake. Finally, Partha Sarathi Mukherjee
and colleagues reported on baseline knowledge levels
among newly diagnosed HBV and HCV patients in West
Bengal, India. Additionally, a blog post has been pub-
lished in conjunction with the thematic series, detailing
the accomplishments of a large-scale community HBV
and HCV educational intervention in Mumbai [9].
In summary, we view this thematic series as an affirm-
ation of the widespread enthusiasm for innovative think-
ing about HBV and HCV in the Chinese and Indian
research communities and community-based program
implementers. It is clear that the health crisis brought
on by these diseases cannot be resolved entirely through
“top-down” interventions by national governments only,
and that “bottom-up” approaches are relevant and valu-
able. They will continue to inform strong national re-
sponses. In this regard, we look forward to watching the
world learn from China and India in the years to come.
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